

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **RITZELER, et al.**

Examiner: Roa, Deepak

Application No.: **10/642,970**

Art Unit: **1624**

Filed: **August 18, 2003**

Title: **INDOLE DERIVATIVES OR
BENZIMIDAZOLE DERIVATIVES
FOR MODULATING $\text{I}\kappa\text{B}$ KINASE**

REQUEST FOR PATENT TERM ADJUSTMENT PURSUANT TO 37 C.F.R. § 1.705

Mail Stop Issue Fee
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir,

Pursuant to 37 C.F.R. § 1.705, Applicants request reconsideration of the patent term adjustment indicated on the Notice of Allowance mailed on March 19, 2007. In support thereof, Applicants submit herewith: (1) the requisite fee set forth under 37 C.F.R. § 1.18(e); and (2) a statement of facts forming the basis for patent term correction. Applicants further warrant that any patent granted on this application is not subject to a terminal disclaimer.

Applicants respectfully submit that the patent term adjustment should be 344 days, not 111 days as presently indicated on the Notice of Allowance.

STATEMENT OF THE CORRECT PATENT TERM ADJUSTMENT

I. Applicants Timely Responded to Notice of Missing Parts

In response to a Notice to File Missing Parts dated November 12, 2003, which notified Applicants of an unsigned declaration or oath, Applicants timely filed on January 7, 2004 (via facsimile) a response which included a signed declaration and authorization to charge the deposit account of Aventis Pharmaceuticals Inc. In turn, confirmation of receipt by the United States Patent Office ("the Office") was in the form of an Auto-Reply Facsimile Transmission confirming receipt of 8 pages of the January 7, 2004 Response.

On May 4, 2004 the Office issued a second Notice to File Missing Parts notifying applicants of an unsigned oath or declaration. In a response dated June 16, 2004, applicants filed a timely response which included copies of the previously submitted declaration filed on January 7, 2004. In turn, Applicants received an Auto-Reply Facsimile Transmission from the USPTO confirming receipt on applicants' June 16, 2004 submission.

On January 5, 2005 the Office issued a Notice of Abandonment for failure to timely or properly reply to the Notice to File Missing Parts dated May 4, 2004. In response, Applicants timely filed, on March 3, 2005, a Petition to Withdraw the Office's holding of Abandonment, which included copies of Applicant's responses filed on January 7, 2004 and June 16, 2004. Subsequently, the Office issued a Withdrawal of the Previously Sent Notice of Abandonment. The Withdrawal indicated that the Notice of Abandonment dated January 5, 2005 was sent in error.

II. Applicants Engaged in Reasonable Efforts

Applicants engaged in reasonable efforts, and respectfully assert that the May 4, 2004 Notice to File Missing Parts, and subsequent January 5, 2005 Notice of Abandonment were issued by the Office in error. Accordingly, Applicants respectfully submit that the proper calculation of 344 days cannot reflect a failure to engage in reasonable efforts by the Applicant. Thus, Applicants request the aforementioned Application Adjustment of Patent Term under 35 USC 154(b) to be corrected from the 111 days listed on the Notice of Allowance, to an accurate 344 days.

The Commissioner is authorized to charge the \$200.00 fee set forth in §1.18(e) required by 37 C.F.R. §1.705(b)(1) to Deposit Account No. 18-1982. The Commissioner is also authorized to charge any additional fees required by this paper or credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,



Robert J. Kajubi, Reg. No. 55,312
Attorney/Agent for Applicant

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3115
Telefax: 908-231-2626

Docket No. DEAV2002/0063 US NP